Drug Policy Watch · State Brief 2026

Iowa

Snapshot (structured)

Adult-use cannabis: Illegal. No legalization or decriminalization; possession of any amount is a misdemeanor. Legalization bills are filed annually by Democrats and die in the Republican-controlled legislature.
Medical cannabis: Limited. Iowa runs a restrictive Medical Cannabidiol (CBD) program, not a full medical marijuana program. No smokable flower; products are oils, capsules, tinctures, and similar. Purchases capped at 4.5 grams of THC per patient per 90 days (with practitioner exceptions for terminal or established patients). HF 990 (signed June 11, 2026) doubled the number of licensed dispensaries from five to ten and opened registration to qualifying out-of-state patients; the program stays CBD/extract-only with no flower and the same 4.5 grams per 90 day cap, and the manufacturer count was not increased.
Home grow: Prohibited (both for adult use and medical patients).
Intoxicating hemp / hemp THC: Restricted. Consumable hemp limited to 4 mg total THC per serving and 10 mg per container (HF 2605, effective July 1, 2024); inhalable/smokable hemp products banned. Exposed to the federal total-THC redefinition taking effect November 12, 2026.
Psychedelics: Illegal. A PTSD-only therapeutic psilocybin bill (HF 978) passed the House in 2025 and advanced through Senate committee in 2026 but died without a Senate floor vote.
Broad decriminalization: None.
Harm reduction: Among the most restrictive states. Fentanyl test strips broadly banned; syringe services programs not authorized; naloxone available via pharmacy standing order but community/nonprofit distribution restricted.
Governor (party): Kim Reynolds (Republican). Not seeking reelection in 2026.
Legislature control: Republican trifecta; Republican supermajorities in both the House and Senate.
Citizen ballot initiatives allowed: No. Iowa has no statewide citizen initiative or referendum process.
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis is illegal in Iowa. There is no decriminalization; possession of any amount is a misdemeanor punishable for a first offense by up to 6 months in jail and a fine of up to roughly $1,000, with escalating penalties for repeat offenses (https://norml.org/laws/iowa-penalties-2/, https://lawshield.us/laws/marijuana-possession/iowa/).

Iowa's only legal access is its Medical Cannabidiol program, established by SF 2360 in 2014 and expanded by HF 524 in 2017 and later acts. It is administered by the Iowa Department of Health and Human Services (HHS) through its Office/Bureau of Medical Cannabidiol (https://hhs.iowa.gov/health-prevention/medical-cannabis, https://www.mpp.org/states/iowa/summary-iowas-medical-cannabidiol-program/). The program is deliberately narrow: - No raw/smokable flower; products are oils, capsules, tinctures, topicals, and similar forms; smoking is not permitted. - Patients with a registry card may purchase up to 4.5 grams of THC per 90 days, with practitioner-authorized exceptions for terminal patients (life expectancy under one year) or established patients for whom the practitioner finds 4.5 grams insufficient (https://www.mpp.org/states/iowa/summary-iowas-medical-cannabidiol-program/). - Note: some commercial sources cite a "3% THC cap" or "30% THC extract" figure. These appear to conflate older or product-specific rules; the well-documented binding limit is the 4.5 g per 90 day purchase cap. Treat percentage-cap claims as unconfirmed pending the current HHS rule text.

Market structure: tightly controlled and small. The program licenses two manufacturers and, following HF 990 (signed June 11, 2026), up to ten dispensaries, doubled from the prior cap of five; that same law also opened registration to qualifying out-of-state patients. As of 2026, the two manufacturers commonly identified are MedPharm Iowa (Des Moines) and Bud and Mary's / Iowa Cannabis Company; a third manufacturer, Iowa Relief (Cedar Rapids, owned by Acreage Holdings), closed and surrendered its license. HF 990 did not add any manufacturer licenses, so the supply still runs through the two manufacturers. Dispensaries operate in locations including Windsor Heights, Sioux City, Iowa City, Waterloo, and Council Bluffs (https://www.mpp.org/states/iowa/summary-iowas-medical-cannabidiol-program/, https://cannabisiowa.org/). There is no broad commercial market, no recreational tax, and no open licensing; vertical integration is effectively built in to the two-manufacturer model. Multi-state operator presence is limited and has been shrinking (Acreage exit).

Key 2026 actions: - HF 2206 (adult-use legalization): introduced January 29, 2026, sponsored by 15 House Democrats (primary sponsor reported as Rep. Jerome Amos Jr.); referred to House Judiciary and went no further (https://legiscan.com/IA/bill/HF2206/2025, https://littlevillagemag.com/iowa-republicans-keep-killing-legal-marijuana-hopes/). - A medical/hemp bill to expand the program and clarify allowable forms (HF 950) was filed (https://legiscan.com/IA/text/HF950/id/3167831). - HF 990 (dispensary expansion and out-of-state access): Gov. Reynolds signed HF 990 on June 11, 2026, doubling the number of licensed medical dispensaries from five to ten and creating a pathway for qualifying out-of-state patients to buy Iowa-authorized products; the program stays CBD/extract-only with no flower and the same 4.5 grams per 90 day THC cap, and the manufacturer count was not increased (NORML, June 11, 2026, corroborated by The Gazette).

Hemp

Iowa regulates consumable hemp under Iowa Code Chapter 204 and HF 2605 (90th General Assembly, effective July 1, 2024). Consumable hemp products are limited to no more than 4 mg total THC per serving and 10 mg total THC per container, and inhalable/smokable hemp products (flower and vapes) are banned from sale or shipment into the state (https://www.cannabisregulations.ai/state-legality/iowa-delta-9, https://www.atlrx.com/blogs/thca/is-thca-legal-in-iowa/).

Effective January 1, 2025, hemp cultivation licensing in Iowa moved from the Iowa Department of Agriculture and Land Stewardship to the USDA, while HHS continues to regulate the manufacture and sale of consumable hemp products (https://iowaagriculture.gov/hemp).

Federal exposure: On November 12, 2025, Congress amended the federal definition of hemp (reported as Section 781 of an appropriations measure), shifting from a Delta-9-only standard to a total-THC standard, with the change taking effect November 12, 2026. This is the most significant change to federal hemp law since the 2018 Farm Bill and could sweep many currently legal hemp-derived THC products out of compliance nationwide. Analysts warn Iowa's Chapter 204 framework is on a collision course with the new federal standard and needs legislative reconciliation (https://weedpress.org/2026/01/12/iowas-chapter-204-hemp-framework-is-headed-for-a-federal-collision-and-the-legislature-needs-to-fix-it/).

Recent state action (2026): House Study Bill 753, an agriculture bill, would classify raw hemp as an agricultural commodity (protecting farmers growing, transporting, and selling the crop), separate naturally grown hemp from chemically altered/synthesized products, cap THC in hemp edibles, ban inhalable hemp, and preempt local hemp rules so producers face one statewide standard. It cleared committee 19-0 (2 excused) on February 19, 2026 (https://www.kcrg.com/2026/02/27/iowa-bill-would-classify-hemp-agricultural-commodity-restrict-some-products/, https://legiscan.com/IA/text/HSB279/id/3150276). Final enactment status of HSB 753 is unconfirmed in available sources; verify at https://www.legis.iowa.gov/law/statutory/acts/enrolledBills.

Psychedelics

Psychedelics remain illegal in Iowa. There is no decriminalization.

A therapeutic-access effort has advanced further than in most conservative states. HF 978 would create a regulated, PTSD-only medical psilocybin program: in-person administration in clinical settings under psychiatric/medical supervision, patients 21 or older, a state Psilocybin Production Establishment Licensing Board (or oversight folded into the existing Medical Cannabidiol Advisory Board) under HHS, and a cap of about 5,000 patients, with license applications contemplated to open July 1, 2026 (https://www.marijuanamoment.net/iowa-lawmakers-unanimously-approve-bill-to-create-psilocybin-program-that-would-treat-up-to-5000-patients-with-ptsd/, https://iowacapitaldispatch.com/2026/03/18/bill-to-establish-state-psilocybin-program-approved-by-senate-subcommittee/).

History and 2026 fate: The Iowa House passed HF 978 by 84-6 in April 2025 (https://iowacapitaldispatch.com/2025/04/21/iowa-house-passes-bill-to-establish-state-psilocybin-program/). In the 2026 session it moved through the Senate, clearing a subcommittee and the Senate Health and Human Services Committee (reported 16-1, 1 abstain) and the Senate Ways and Means Committee, but it did not reach the Senate floor before adjournment and so died for the session (https://www.iowapublicradio.org/state-government-news/2026-03-19/senate-panel-approves-bill-expanding-access-to-hallucinogenic-treatments-in-iowa, https://www.newsfromthestates.com/article/2026-legislative-session-over-heres-what-passed-failed-and-what-already-iowa-law). Because Iowa runs two-year general assemblies, the bill could potentially be revived in the 2027 session within the same 91st General Assembly; treat 2027 procedural status as unconfirmed.

Broader drug policy

Decriminalization: None for cannabis or other drugs.

Harm reduction (notably restrictive): - Fentanyl test strips: Iowa is one of only a small handful of states that broadly bans fentanyl test strips (reported alongside Idaho, Indiana, North Dakota, and Texas; roughly 45 states plus D.C. permit them). Advocates and the state Attorney General have called for legalization, but bills have repeatedly stalled (https://filtermag.org/iowa-fentanyl-test-strips-legalize/, https://www.thegazette.com/news/iowa-attorney-general-calls-for-legalizing-fentanyl-test-strips/). - Syringe services programs: Not legally authorized in Iowa, one of a small group of states without legal SSPs (https://siouxcityjournal.com/news/state-and-regional/experts-say-iowa-s-laws-impede-treatments-for-fentanyl/article_eae2d638-3f9b-581d-995d-68a9dcf34ae0.html). - Naloxone: Available without an individual prescription via a 2016 pharmacy standing-order law, but distribution outside a pharmacy (by community organizations and nonprofits) has been restricted, with ongoing calls to broaden access (https://siouxcityjournal.com/news/state-and-regional/experts-say-iowa-s-laws-impede-treatments-for-fentanyl/article_eae2d638-3f9b-581d-995d-68a9dcf34ae0.html).

Sentencing and expungement: Marijuana possession carries jail-eligible misdemeanor penalties. Iowa has only a limited expungement pathway for certain misdemeanor possession convictions; there is no automatic cannabis record clearing. Democratic legalization bills have included decriminalization and expungement provisions, but these have not advanced (https://norml.org/laws/iowa-penalties-2/, https://littlevillagemag.com/iowa-republicans-keep-killing-legal-marijuana-hopes/).

Other 2026 scheduling action: The Iowa House passed a bill to designate kratom as a Schedule I hallucinogenic substance, a prohibitionist move running counter to liberalization trends (https://iowacapitaldispatch.com/2026/03/17/bill-outlawing-kratom-as-a-schedule-i-drug-passes-iowa-house/). Final enactment status unconfirmed.

Overdose and treatment: Iowa's restrictive harm-reduction posture (no SSPs, banned test strips, limited community naloxone) is repeatedly cited by public-health experts as impeding fentanyl response (https://siouxcityjournal.com/news/state-and-regional/experts-say-iowa-s-laws-impede-treatments-for-fentanyl/article_eae2d638-3f9b-581d-995d-68a9dcf34ae0.html).

Political landscape

Governor: Kim Reynolds (Republican), who announced she will not seek reelection in 2026 (https://www.nbcnews.com/politics/2026-election/iowa-republican-gov-kim-reynolds-wont-seek-re-election-2026-rcna200891). Reynolds has been broadly unsupportive of cannabis legalization.

Party control: Republican trifecta with Republican supermajorities in both chambers (https://ballotpedia.org/Party_control_of_Iowa_state_government). Reported leadership includes Senate President Amy Sinclair (R) and House Speaker Pat Grassley (R) (https://www.yahoo.com/news/articles/iowa-gop-legislative-leaders-stress-unity-as-2026-session-opens).

Key committees for drug policy: House Judiciary (criminal penalties and legalization bills), House and Senate Health and Human Services (medical cannabis, psilocybin), Senate and House Ways and Means (taxation/revenue provisions), and Agriculture (hemp). Specific chair names are unconfirmed in the sources gathered; verify at https://www.legis.iowa.gov.

Reform proponents: Iowa House Democrats have repeatedly led legalization, decriminalization, and expungement efforts (HF 2206 and predecessors). Democratic gubernatorial candidate Rob Sand has campaigned on legalizing and regulating adult-use cannabis (with regulation under the Alcoholic Beverages Division) and regulating hemp products (https://www.thegazette.com/news/elections/state/legalize-cannabis-iowa-gubernatorial-candidate-rob-sand-says/article_bc5053cf-722b-4c58-b853-3e2903c9e59a.html). The psilocybin bill has had notable bipartisan support, passing the House 84-6.

Opponents/skeptics: The Republican legislative majority has blocked adult-use legalization for roughly a decade; Gov. Reynolds has been a consistent skeptic. Named individual opponents on specific 2026 bills are unconfirmed beyond the general majority posture; verify before attributing.

Ballot initiatives

Iowa does not allow statewide citizen-initiated ballot measures or veto referendums. It is one of about two dozen states with no initiative/referendum process; voters have never approved creating one (https://ballotpedia.org/Laws_governing_ballot_measures_in_Iowa, https://www.bleedingheartland.com/2024/08/13/what-if-iowa-had-citizen-led-ballot-initiatives/). Constitutional amendments can reach the ballot only after passage by two successive general assemblies in identical form, then a public vote. Some home-rule cities may grant local initiative/referendum powers under Iowa Code 372.3, but this cannot legalize cannabis or psychedelics, which are governed by state law. No pending 2026 statewide cannabis, psychedelic, or drug-policy ballot measure exists because the mechanism does not exist (https://ballotpedia.org/Iowa_2026_ballot_measures).

Equity and expungement

Iowa's medical cannabidiol licensing has no social-equity carve-outs; it is a closed two-manufacturer/ten-dispensary model (the dispensary cap was raised from five to ten by HF 990, signed June 11, 2026, which also added out-of-state patient registration) with no equity preference, residency-based equity tier, or microbusiness pathway. There is no adult-use market, so no adult-use social-equity program exists. On records, Iowa offers only a limited petition-based expungement for certain misdemeanor possession convictions; there is no automatic cannabis expungement or sealing. Democratic legalization bills have proposed expungement, but none have passed (https://norml.org/laws/iowa-penalties-2/, https://littlevillagemag.com/iowa-republicans-keep-killing-legal-marijuana-hopes/). Net effect: the small legal market is concentrated among a couple of license holders, and people with prior convictions get no broad relief.

Market and barriers

License caps: Two manufacturer licenses and up to ten dispensary licenses in the medical CBD program (HF 990, signed June 11, 2026, doubled the dispensary cap from five to ten and added out-of-state patient registration; the manufacturer count was not increased) (https://www.mpp.org/states/iowa/summary-iowas-medical-cannabidiol-program/).
Approximate licensees: 2 manufacturers, up to 10 dispensaries (raised from 5 by HF 990); one manufacturer (Iowa Relief) recently exited (https://cannabisiowa.org/).
Patient purchase cap: 4.5 g THC per 90 days (with exceptions) (https://www.mpp.org/states/iowa/summary-iowas-medical-cannabidiol-program/).
Hemp THC caps: 4 mg total THC per serving, 10 mg per container; inhalable hemp banned (https://www.cannabisregulations.ai/state-legality/iowa-delta-9).
Taxes: No recreational excise tax (no adult-use market). HF 2206 would have created excise taxes had it advanced. Specific medical program fees, application fees, capital requirements, and residency requirements are not detailed in the sources gathered and are unconfirmed; verify with HHS Office of Medical Cannabidiol (https://hhs.iowa.gov/health-prevention/medical-cannabis/manufacturers-and-dispensaries).

Enclosure read

Iowa is heavily fenced. Legal cannabis access is restricted to a tiny, closed, vertically integrated medical CBD program (two manufacturers, up to ten dispensaries after HF 990 doubled the cap from five on June 11, 2026, no flower, no home grow) with no equity or microbusiness on-ramp. Because HF 990 added dispensaries and out-of-state patients but did not add manufacturer licenses, the few incumbent manufacturers still capture the entire legal supply. Adult-use legalization, decriminalization, and expungement are blocked year after year by a Republican supermajority and a skeptical (outgoing) governor, and Iowans have no citizen-initiative escape valve to go around the legislature. Hemp is being narrowed (low THC caps, inhalable ban, looming federal total-THC redefinition), and harm reduction is among the most restrictive in the country (banned fentanyl test strips, no syringe services, limited community naloxone). The one genuinely open-feeling movement, therapeutic psilocybin, is itself a capped (about 5,000 patients), licensed, PTSD-only model that still failed to clear the Senate.

Justification for 4/5: nearly every avenue (adult use, home grow, broad medical, open licensing, harm reduction, ballot initiative) is closed or tightly controlled, and consolidation is structural in the two-manufacturer model. It is not a 5 only because a narrow medical CBD program and a near-miss bipartisan psilocybin bill show some movement and some legal access exists.

What to watch next

Federal hemp deadline: November 12, 2026, when the new federal total-THC definition of hemp takes effect, likely forcing Iowa to reconcile its Chapter 204 framework (https://weedpress.org/2026/01/12/iowas-chapter-204-hemp-framework-is-headed-for-a-federal-collision-and-the-legislature-needs-to-fix-it/).
2026 elections: Open governor's race (Reynolds not running); Democrat Rob Sand running on legalization. A change in the governorship or chamber margins would reshape prospects.
2027 session: The 92nd General Assembly is expected to convene in January 2027 (exact date unconfirmed; Iowa typically convenes the second Monday of January). Psilocybin and cannabis advocates have signaled 2027 as the next real window (https://littlevillagemag.com/iowa-republicans-keep-killing-legal-marijuana-hopes/).
Psilocybin revival: HF 978 reached Senate Ways and Means in 2026; watch whether it gets a Senate floor vote early in 2027.
Hemp/HSB 753 and kratom Schedule I bill: confirm final enactment via the enrolled-bills list (https://www.legis.iowa.gov/law/statutory/acts/enrolledBills).
The 2026 session adjourned sine die in early May 2026 (reported May 3), so no further state legislative action until 2027 (https://iowacapitaldispatch.com/2026/05/04/the-2026-legislative-session-is-over-heres-what-passed-failed-and-what-is-already-iowa-law/).

Regulators

Iowa Department of Health and Human Services (HHS), Office/Bureau of Medical Cannabidiol: administers the medical cannabidiol program and regulates consumable hemp product manufacture and sale (https://hhs.iowa.gov/health-prevention/medical-cannabis).
Medical Cannabidiol Advisory Board (under HHS): advises on qualifying conditions and program changes; proposed to also oversee psilocybin under HF 978.
USDA: oversees hemp cultivation licensing in Iowa as of January 1, 2025 (https://iowaagriculture.gov/hemp).
Iowa Department of Agriculture and Land Stewardship: prior hemp cultivation regulator; retains agricultural roles (https://iowaagriculture.gov/hemp).
Iowa Alcoholic Beverages Division: proposed (not current) adult-use cannabis regulator under candidate Rob Sand's plan and some legalization bills.
Iowa Board of Pharmacy / law enforcement: controlled-substance scheduling and enforcement.

Federal exposure (2026)

This section maps the 2026 federal drug-policy levers onto Iowa's specific posture. The short version: Iowa is exposed mostly on hemp and harm reduction, and almost untouched by the rescheduling and banking changes, because it has no adult-use market and only a tiny closed medical program.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. The practical federal effect for Iowa is narrow. Iowa runs a closed Medical Cannabidiol program with two licensed manufacturers (commonly identified as MedPharm Iowa and Bud and Mary's / Iowa Cannabis Company) and up to ten dispensaries (doubled from five by HF 990, signed June 11, 2026). Because that program is state-licensed medical cannabis, its operators sit in exactly the category that gains relief from Internal Revenue Code Section 280E, the rule that bars ordinary business deductions for sellers of Schedule I and II controlled substances. Ending 280E for the medical category improves the after-tax economics of Iowa's two manufacturers and their dispensaries, which is a consolidation tailwind for the existing incumbents and does nothing for anyone trying to enter, because Iowa does not open new licenses. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not cover state cannabis businesses as a matter of federal legality; Iowa product still cannot lawfully cross state lines, and there is no adult-use category in Iowa to benefit at all. Net: the one tangible federal upside in 2026, 280E relief, flows to the two incumbent manufacturers and the handful of dispensaries, reinforcing rather than loosening the closed structure.

Hemp and the November 12, 2026 cliff. This is Iowa's single largest federal exposure. The FY2026 agriculture appropriations measure (reported as Section 781, Rep. Andy Harris R-MD) narrowed the federal definition of hemp from a Delta-9-only standard to a total-THC standard of roughly 0.4 mg THC per container, recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The proposed H.R.7010 delay was not enacted, and the 2026 Farm Bill (H.R.7567) keeps the ban, so the cliff is live. Iowa already caps consumable hemp at 4 mg total THC per serving and 10 mg per container (HF 2605, effective July 1, 2024) and already bans inhalable/smokable hemp, so Iowa's state floor is far above the new federal ceiling. The interaction: products that are legal under Iowa's 10 mg per container cap will mostly become federally unlawful under the roughly 0.4 mg per container total-THC standard, because the federal number is more than an order of magnitude stricter. Federal illegality removes interstate shipment and federal protection for those products even where Iowa law still tolerates them, and it pressures Iowa to reconcile Chapter 204 downward to match. Iowa's 2026 hemp legislation (House Study Bill 753, which would classify raw hemp as an agricultural commodity, cap edible THC, ban inhalable hemp, and preempt local rules) addresses the state framework but does not insulate Iowa hemp businesses from the federal redefinition; final enactment of HSB 753 is unconfirmed, verify at https://www.legis.iowa.gov/law/statutory/acts/enrolledBills. Bottom line: most of Iowa's already-restricted consumable hemp market is set to be federally recriminalized in November 2026, and the federal read favors large incumbents while fencing out small hemp actors.

Banking. SAFER Banking has stalled in Congress, so there is no federal safe-harbor for financial institutions serving state cannabis operators. For Iowa this is a marginal issue rather than a central one, because Iowa has no adult-use market and only two medical manufacturers and a few dispensaries; the universe of Iowa cannabis businesses needing banking is tiny. The stalled bill mainly means the existing incumbents continue to face banking friction, another small structural advantage for well-capitalized operators who can absorb it.

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no FDA approval yet. Iowa's own PTSD-only therapeutic psilocybin bill (HF 978) passed the House 84-6 in 2025 and cleared Senate committees in 2026 but died without a Senate floor vote. The contrast matters: the federal pathway is a clinical, FDA-centered medicalize-and-control route that, if it ever yields approval, would place psilocybin in the hands of pharmaceutical and clinical incumbents and could reschedule it nationally; Iowa's bill was itself a capped (about 5,000 patients), licensed, clinician-supervised, PTSD-only model. Both routes are medicalize-and-control rather than decriminalization, and neither is operative in Iowa today, the state bill having died and the federal review not having produced an approval.

Harm reduction. The SAMHSA guidance of April 24, 2026 bars federal funds for fentanyl test strips, clean syringes, and sterile water, while continuing to support naloxone. For most states this guidance withdraws federal money from harm-reduction supplies. For Iowa the marginal effect is limited precisely because Iowa already bans fentanyl test strips and does not legally authorize syringe services programs, so there was little federally funded test-strip or syringe activity in Iowa for the new guidance to defund. The guidance does, however, remove any near-term federal funding lever that advocates might have used to push Iowa toward authorizing those services, and it aligns federal policy with Iowa's already-restrictive posture. Naloxone, which Iowa permits via a 2016 pharmacy standing order, remains federally supported, so the one harm-reduction tool Iowa does allow keeps its federal backing.

Fentanyl. The HALT Fentanyl Act (July 17, 2025) permanently placed fentanyl-related substances in Schedule I federally. This reinforces, and federalizes permanently, the prohibitionist direction Iowa is already moving in, consistent with Iowa's 2026 House-passed bill to schedule kratom as Schedule I. It adds no liberalizing pressure.

Patient access and rights

This section covers what Iowa law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Iowa has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Iowa is not among them. The absence is the finding: an Iowa patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Iowa protects a patient in one of the six areas, parenting. Iowa Code Section 124E.12(5) bars removing a minor from a parent, or denying a parent custody or visitation, based solely on the parent's authorized medical use. A review of Section 124E.12 found no protection for employment, housing, an organ transplant list, or school enrollment, and its general medical-care language provides only an affirmative defense, not a broad protection. Those gaps are the finding.

Out-of-state patients: Iowa recognizes an out-of-state card for possession only, as an affirmative defense; a visitor cannot purchase at an Iowa dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Iowa has not enacted a Ryan's Law. The broader protections above are a creature of Iowa law, not federal law.

Sources: Iowa patient protections, Iowa Code Section 124E.12.

Analysis: the enclosure read in depth

Who is fenced out. In Iowa, almost everyone outside two companies. Legal cannabis supply is restricted to a closed program with two manufacturer licenses and up to ten dispensaries (doubled from five by HF 990 in June 2026), no raw or smokable flower, and no home grow for patients or anyone else. There is no adult-use market, so there is no entry point for new cultivators, processors, retailers, or microbusinesses, and there is no social-equity or microbusiness on-ramp of any kind. People with prior cannabis convictions get no broad relief, only a limited petition-based misdemeanor expungement. Small hemp retailers, already squeezed by Iowa's 10 mg per container cap and inhalable ban, face federal recriminalization of most of their products in November 2026. Harm-reduction providers are fenced out by the test-strip ban and the absence of legal syringe services. Would-be psilocybin therapy providers were fenced out when HF 978 died in the Senate.

Who consolidates. The two incumbent manufacturers and the few dispensaries. They hold the entire legal cannabis supply, the program is vertically integrated by design, and the 2026 federal 280E relief for state-licensed medical cannabis lowers their tax burden without admitting any new competitor. Multi-state operator presence has actually been shrinking (Iowa Relief, owned by Acreage Holdings, surrendered its license), which concentrates the remaining legal market further into the two survivors. HF 990 (signed June 11, 2026) roughly doubled dispensary licenses from five to ten and added out-of-state patient registration, which modestly widens retail but stays within a capped, state-chosen set, not an open market, and it left the two-manufacturer supply bottleneck untouched.

State-plus-federal interaction. The two layers reinforce each other in the enclosure direction. Federally, 280E relief rewards the existing medical incumbents, the hemp redefinition recriminalizes small-actor products, stalled SAFER Banking keeps a friction cost that favors the well-capitalized, the SAMHSA guidance defunds the harm-reduction tools Iowa already bans, and HALT Fentanyl permanently federalizes prohibition. At the state level, a Republican supermajority and a skeptical outgoing governor block adult use, decriminalization, and expungement; there is no home grow; and there is no citizen ballot initiative process to route around the legislature. Every federal lever that could have opened space in 2026 (rescheduling, banking, psychedelics, harm reduction) either does not reach Iowa or reaches it in the consolidating direction, while the one federal lever that bites hardest (the hemp cliff) narrows the market further. The federal enclosure read, medicalize-and-control favoring large incumbents and fencing out small actors and hemp, lands squarely on Iowa.

Near-absence of commons counter-moves. There is very little pushing the other way. Iowa has no ballot initiative, so the public cannot create a commons-style opening by referendum. Home grow, the most basic decommodified access route, is prohibited outright. There are no cooperatives, no microbusiness tier, no equity licensing, and no decriminalization. The only genuinely open-feeling movements were Democratic legalization bills (which die annually) and the PTSD psilocybin bill (which died in the Senate in 2026), and even the psilocybin model was a capped, licensed, clinical program rather than a commons. The 2026 elections (open governor's race, Democrat Rob Sand running on legalization) and a possible 2027 revival of psilocybin are the only realistic counter-pressures on the horizon, and both are contingent and unconfirmed in outcome.

Why 4 out of 5. Nearly every avenue is closed or tightly controlled: no adult use, no home grow, no broad medical access, no open licensing, no equity tier, restrictive harm reduction, and no ballot initiative escape valve. Consolidation is structural in the two-manufacturer model, and the 2026 federal changes mostly reinforce that structure (280E relief to incumbents, hemp recriminalization of small actors, harm-reduction defunding aligned with Iowa's bans). It is held to a 4 rather than a 5 only because a narrow legal medical CBD program does exist and provides some legal access, a near-miss bipartisan psilocybin bill showed real legislative movement, and an open 2026 governor's race plus a two-year general assembly leave a live, if narrow, path to change in 2027.

Active legislation (2026)

This list covers significant bills and is not exhaustive. Iowa runs two-year general assemblies (the current one is the 91st, 2025-2026), so 2025-introduced bills can carry into 2026. For the full tracker, see LegiScan (https://legiscan.com/IA), the Iowa Legislature site (https://www.legis.iowa.gov).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

Kratom Schedule I bill Designate kratom as a Schedule I hallucinogenic substance (Passed House (2026); Senate/enactment unconfirmed)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HF 2206	Adult-use marijuana legalization; retail licensure, excise taxes, penalties	House	Introduced Jan 29, 2026; referred to Judiciary; died in committee	15 House Democrats; primary sponsor reported as Rep. Jerome Amos Jr. (others incl. Wichtendahl, Levin, Scholten, Wessel-Kroeschell; full list per LegiScan)
HF 978	PTSD-only therapeutic psilocybin program (carryover)	Originated House, advanced in Senate	Passed House 2025 (84-6); cleared Senate HHS and Ways and Means committees in 2026; died without Senate floor vote	Unconfirmed primary sponsor; verify at LegiScan
HSB 753	Classify raw hemp as agricultural commodity; cap edible THC; ban inhalable hemp; preempt local rules	House (study bill)	Cleared committee 19-0 (2 excused) Feb 19, 2026; final enactment unconfirmed	House Agriculture committee bill; sponsor unconfirmed
HF 950	Hemp products and definition/possession/allowable forms of medical cannabidiol	House	Introduced; status unconfirmed	Unconfirmed; verify at LegiScan
HSB 279	Hemp/consumable hemp regulation (2025-2026)	House (study bill)	Introduced; status unconfirmed	Unconfirmed; verify at LegiScan
Kratom Schedule I bill	Designate kratom as a Schedule I hallucinogenic substance	House	Passed House (2026); Senate/enactment unconfirmed	Unconfirmed; verify at LegiScan
HF 990 (medical dispensary expansion)	Double allowed medical CBD dispensaries from five to ten; add out-of-state patient registration (manufacturer count unchanged; still CBD/extract-only, no flower)	Both	Signed by Gov. Reynolds June 11, 2026; dispensary cap raised from five to ten and out-of-state patient access added. (source)	Unconfirmed; verify at LegiScan and enrolled bills

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →